We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+20.28%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$14.6M
(+12%)
Cap. Flow
+$2.27M
Cap. Flow % of AUM
Cap. Flow %
1.69%
Top 10 Holdings %
Top 10 Hldgs %
93.35%
Holding
19
New
2
Increased
1
Reduced
1
Closed
2
Avg Time Held
1.2
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CASC
Cascadian Therapeutics
CASC
|
+$3.89M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$1.16M |
| 3 |
IMDZ
Immune Design
IMDZ
|
+$896K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NOVN
Novan
NOVN
|
+$1.53M |
| 2 |
ANTH
Anthera Pharmaceuticals
ANTH
|
+$1.17M |
| 3 |
DRNA
Dicerna Pharmaceuticals
DRNA
|
+$973K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q1 2017 Portfolio in Review
As of Q1 2017, Abingworth held 19 positions worth $134M, up 12% from $120M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Abingworth's Q1 2017 filing shows 2 new, 1 increased, 1 reduced and 2 closed positions. Its largest new stake was Cascadian Therapeutics: 925,000 shares worth $3.83M. The largest sale was Novan, an estimated $1.53M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Abingworth's largest Q1 2017 buy was Cascadian Therapeutics: 925,000 shares worth $3.83M.
- Abingworth added most to Immune Design in Q1 2017, an estimated $896K increase.
- Abingworth's biggest Q1 2017 reduction was Novan, cutting an estimated $1.53M.
- Abingworth fully exited Anthera Pharmaceuticals in Q1 2017, selling an estimated $1.17M.
- Abingworth's ten largest holdings make up 93% of its $134M portfolio in Q1 2017.
- Abingworth opened 2 new positions and closed 2 in Q1 2017.
- Abingworth's portfolio value rose 12% quarter-over-quarter to $134M.
Based on Abingworth's 13F filing for Q1 2017, filed 15 May 2017.